Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
5-day change
1st Jan Change
0.76
USD
-2.56%
-5.94%
-63.46%
Presentation Operator MessageOperator (Operator)Good afternoon, ladies and gentlemen, and welc...
Transcript : Eyenovia, Inc., Q1 2024 Earnings Call, May 15, 2024
May. 15
Eyenovia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 15
CI
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension
Apr. 25
CI
Eyenovia to Weigh Potential Sale, Other Strategic Alternatives
Apr. 08
MT
Eyenovia Explores Wide Range of Strategic Alternatives
Apr. 08
CI
Transcript : Eyenovia, Inc., Q4 2023 Earnings Call, Mar 18, 2024
Mar. 18
Eyenovia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 18
CI
North American Morning Briefing : Investors -2-
Mar. 18
DJ
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
Mar. 13
CI
Eyenovia Reports FDA Approval for Formosa's Post-Op Eye Inflammation, Pain Treatment
Mar. 05
MT
US FDA approves Eyenovia's eye drug, Formosa Pharma says
Mar. 04
RE
Eyenovia, Inc Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
Feb. 13
CI
Eyenovia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 13
CI
Transcript : Eyenovia, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Nov. 13
Eyenovia, Inc. Appoints Michael Geltzeiler to Serve on the Board and as the Chair of the Audit Committee of the Board
Nov. 09
CI
Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
Nov. 02
CI
William Blair Initiates Eyenovia at Outperform Rating
Nov. 01
MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
23-08-25
MT
Eyenovia Prices $12 Million Registered Direct Offering
23-08-25
MT
Insider Buy: Eyenovia
23-08-17
MT
Eyenovia Acquires US Rights to Eye Surgery Drug From Formosa
23-08-16
MT
Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of App13007 for the Treatment of Inflammation and Pain Following Ocular Surgery
23-08-16
CI
Transcript : Eyenovia, Inc., Q2 2023 Earnings Call, Aug 10, 2023
23-08-10
Eyenovia, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-10
CI
Eyenovia, Inc. Announces First Commercial Sale of Mydcombi
23-08-03
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.
More about the company
Last Close Price
0.76
USD
Average target price
9
USD
Spread / Average Target
+1,084.21%
Consensus
1st Jan change
Capi.
-63.46% 40.94M +45.82% 765B -6.16% 354B +19.86% 331B +9.32% 299B +18.91% 248B -1.55% 219B +11.24% 216B +5.90% 164B -0.73% 162B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1